MCID: HYP085
MIFTS: 46

Hypothalamic Disease

Categories: Rare diseases, Endocrine diseases, Neuronal diseases

Aliases & Classifications for Hypothalamic Disease

MalaCards integrated aliases for Hypothalamic Disease:

Name: Hypothalamic Disease 12 14
Hypothalamic Dysfunction 72 49
Hypothalamic Diseases 41 69
Hypothalamic Dysfunction Syndromes 69
Hypothalamic Disorder 51

Classifications:



External Ids:

Disease Ontology 12 DOID:1931
MeSH 41 D007027
ICD10 32 E23.3

Summaries for Hypothalamic Disease

NIH Rare Diseases : 49 Hypothalamic dysfunction refers to a condition in which the hypothalamus is not working properly. The hypothalamus produces hormones that control body temperature, hunger, moods, release of hormones from many glands such as the pituitary gland, sex drive, sleep, and thirst. The signs and symptoms patients have vary depending on the hormones missing. A number of different causes including anorexia, bleeding, genetic disorder, tumors, and more have been linked to hypothalamic dysfunction. Treatment depends on the cause of the hypothalamic dysfunction. Last updated: 4/13/2010

MalaCards based summary : Hypothalamic Disease, also known as hypothalamic dysfunction, is related to prader-willi syndrome and body mass index quantitative trait locus 11. An important gene associated with Hypothalamic Disease is CRH (Corticotropin Releasing Hormone), and among its related pathways/superpathways are G-Beta Gamma Signaling and Peptide ligand-binding receptors. The drugs Hydrocortisone and Prednisone have been mentioned in the context of this disorder. Affiliated tissues include pituitary, testes and brain, and related phenotypes are endocrine/exocrine gland and liver/biliary system

Wikipedia : 72 Hypopituitarism is the decreased (hypo) secretion of one or more of the eight hormones normally produced... more...

Related Diseases for Hypothalamic Disease

Diseases related to Hypothalamic Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 114)
# Related Disease Score Top Affiliating Genes
1 prader-willi syndrome 28.4 GH1 GNRH1 POMC
2 body mass index quantitative trait locus 11 28.0 CRH GH1 GHRH POMC
3 acromegaly 28.0 GH1 GHRH POMC PRL
4 rapid-onset childhood obesity-hypothalamic dysfunction-hypoventilation-autonomic dysregulation syndrome 12.3
5 anophthalmia cleft lip palate hypothalamic disorder 12.0
6 rohhad 11.9
7 shapiro syndrome 11.0
8 fryns microphthalmia syndrome 11.0
9 x-linked lissencephaly with abnormal genitalia 10.9
10 froelich syndrome 10.8
11 melancholia 10.3 CRH PRL
12 postpartum depression 10.2 CRH PRL
13 hypothalamic adipsic hypernatraemia syndrome 10.2
14 endometriosis of uterus 10.2 GNRH1 PRL
15 hypogonadotropism 10.2 GNRH1 PRL
16 anovulation 10.1 GNRH1 PRL
17 fibrous dysplasia/mccune-albright syndrome 10.1 GH1 PRL
18 tsh producing pituitary tumor 10.1 GH1 PRL
19 pseudohypoparathyroidism, type ia 10.1 GH1 PRL
20 pituitary adenoma 1, multiple types 10.1 GH1 PRL
21 endogenous depression 10.1 CRH GNRH1
22 tetrahydrobiopterin deficiency 10.1 GH1 PRL
23 varicocele 10.1 GNRH1 PRL
24 pituitary stalk interruption syndrome 10.1 GH1 PRL
25 craniopharyngioma 10.1 GNRH1 PRL
26 mccune-albright syndrome 10.1 GH1 PRL
27 isolated growth hormone deficiency, type ib 10.1 GH1 GHRH
28 fibrous dysplasia 10.0 GH1 PRL
29 aromatase deficiency 10.0 GH1 GNRH1
30 precocious puberty 10.0 GH1 GNRH1
31 isolated growth hormone deficiency, type ii 10.0 GH1 GHRH
32 isolated growth hormone deficiency 10.0 GH1 GHRH
33 reproductive system disease 10.0 GNRH1 PRL
34 acth deficiency, isolated 10.0 CRH POMC
35 pituitary carcinoma 10.0 CRH POMC
36 dwarfism 10.0 GH1 GHRH
37 fasting hypoglycemia 10.0 CRH POMC
38 adrenal cortical hypofunction 10.0 CRH POMC
39 withdrawal disorder 10.0 CRH POMC
40 persistent fetal circulation syndrome 10.0 CRH POMC
41 ectopic cushing syndrome 10.0 CRH POMC
42 central nervous system organ benign neoplasm 10.0 POMC PRL
43 hypoadrenocorticism, familial 10.0 CRH POMC
44 growth hormone deficiency 9.9 GH1 GHRH
45 premature ovarian failure 1 9.9 GNRH1 PRL
46 mental depression 9.9 CRH POMC
47 adrenal adenoma 9.9 CRH POMC
48 gynecomastia 9.9 POMC PRL
49 thyroid gland disease 9.9 POMC PRL
50 adrenal rest tumor 9.9 GNRH1 POMC

Graphical network of the top 20 diseases related to Hypothalamic Disease:



Diseases related to Hypothalamic Disease

Symptoms & Phenotypes for Hypothalamic Disease

MGI Mouse Phenotypes related to Hypothalamic Disease:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 9.35 CRH GHRH GNRH1 POMC PRL
2 liver/biliary system MP:0005370 9.02 CRH GHRH GNRH1 POMC PRL

Drugs & Therapeutics for Hypothalamic Disease

Drugs for Hypothalamic Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 324)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Hydrocortisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Early Phase 1 50-23-7 657311 5754
2
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
3
Menthol Approved Phase 4 2216-51-5 16666
4
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
5
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1 51-61-6, 62-31-7 681
6
Risperidone Approved, Investigational Phase 4,Phase 3 106266-06-2 5073
7
Octreotide Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 83150-76-9 6400441 383414
8
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
9 Racepinephrine Approved Phase 4 329-65-7
10
Somatostatin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 38916-34-6, 51110-01-1 53481605
11
Cabergoline Approved Phase 4,Phase 3,Phase 2 81409-90-7 54746
12 lanreotide Approved Phase 4,Phase 3,Phase 2,Phase 1 108736-35-2
13
Zinc Approved, Investigational Phase 4,Phase 3,Early Phase 1 7440-66-6 32051 23994
14
Acetaminophen Approved Phase 4 103-90-2 1983
15
Hydromorphone Approved, Illicit Phase 4 466-99-9 5284570
16
Ibuprofen Approved Phase 4 15687-27-1 3672
17
Morphine Approved, Investigational Phase 4 57-27-2 5288826
18
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
19
Methylprednisolone Approved, Vet_approved Phase 4,Phase 2 83-43-2 6741
20
Prednisolone Approved, Vet_approved Phase 4,Phase 2 50-24-8 5755
21
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
22
Cosyntropin Approved Phase 4 16960-16-0 16129617
23
Quinagolide Approved, Investigational Phase 4 87056-78-8, 97805-50-0 105105
24
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2 50-28-2 5757
25
Dexmedetomidine Approved, Vet_approved Phase 4 76631-46-4, 113775-47-6 5311068 56032 68602
26
Cefazolin Approved Phase 4 25953-19-9 33255 656510
27
Cefdinir Approved Phase 4 91832-40-5 6915944
28
Cefuroxime Approved Phase 4 55268-75-2 5479529 5361202
29
Clindamycin Approved, Vet_approved Phase 4 18323-44-9 29029
30
Sulfamethoxazole Approved Phase 4 723-46-6 5329
31
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
32
Liraglutide Approved Phase 4 204656-20-2 44147092
33
Metformin Approved Phase 4 657-24-9 4091 14219
34
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 1 59-30-3 6037
35
leucovorin Approved, Nutraceutical Phase 4,Phase 1 58-05-9 143 6006
36
Butyric Acid Experimental, Investigational Phase 4,Early Phase 1 107-92-6 264
37
Lactitol Investigational Phase 4,Phase 3,Phase 1 585-86-4 3871
38 Anesthetics Phase 4,Phase 1
39 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 1,Early Phase 1
40 Antineoplastic Agents, Hormonal Phase 4,Phase 2,Phase 3,Phase 1
41 Cortisol succinate Phase 4,Phase 3,Phase 2,Early Phase 1
42 glucocorticoids Phase 4,Phase 2,Phase 1
43 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
44 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
45 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
46 Hydrocortisone 17-butyrate 21-propionate Phase 4,Phase 3,Phase 2,Early Phase 1
47 Hydrocortisone acetate Phase 4,Phase 3,Phase 2,Early Phase 1
48 Hydrocortisone-17-butyrate Phase 4,Early Phase 1
49 Antipsychotic Agents Phase 4,Phase 3,Phase 2
50 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 539)

# Name Status NCT ID Phase Drugs
1 Effect of Perioperative Glucocorticoid Replacement on Prognosis of Surgical Patients With Sellar Lesions Unknown status NCT02190994 Phase 4 Hydrocortisone;Prednisone
2 Characterization of Receptors in Non-functioning Pituitary Macroadenomas Unknown status NCT00852501 Phase 4
3 A Multicenter Study to Evaluate the Effects of Switching to Aripiprazole 12 Weeks on the Sexual Dysfunction From Risperidone or Paliperidone in Patients With Schizophrenia Spectrum Disorders or Bipolar Spectrum Disorders Unknown status NCT01742390 Phase 4 Aripiprazole;risperidone or paliperidone
4 Phase IV Clinical Study of Pegylated Somatropin (PEG Somatropin) to Treat Growth Hormone Deficiency Children Unknown status NCT02314676 Phase 4
5 Effects of Sandostatin LAR® in Acromegaly Unknown status NCT01424241 Phase 4 Sandostatin LAR
6 Growth Hormone Feedback to Insulin-like Growth Factor-I (IGF-1) and Oral Glucose Tolerance Test (OGTT) Unknown status NCT00915954 Phase 4
7 Changes of Left Ventricular Mass and Cardiac Function in Patients With Active Acromegaly During Treatment With the Growth Hormone Receptor Antagonist Pegvisomant Unknown status NCT00552851 Phase 4 pegvisomant
8 Reversal of Antipsychotic-Induced Hyperprolactinemia, Weight Gain, Hyperglycemia and Dyslipidemia Unknown status NCT00541554 Phase 4 Abilify (aripiprazole)
9 Analgesia Regimens Following Trans-sphenoidal Surgery for Pituitary Tumors Completed NCT02351700 Phase 4 IV Caldolor (IV Ibuprofen);IV Ibuprofen placebo
10 Evaluation of Efficacy and Hypothalamus-pituitary-adrenal Axis Suppression Due to Corticosteroids Intrabursal Injection Completed NCT01652495 Phase 4 methylprednisolone acetate;Triamcinolone Acetonide
11 Predictive Markers in Chinese Growth Hormone Deficiency (GHD) Children Treated With Saizen® Completed NCT01187550 Phase 4 Recombinant human growth hormone (r-hGH)
12 Adipokine Profile in Patients With Cushing's Disease on Pasireotide Treatment Completed NCT03080181 Phase 4 Pasireotide 0.6 MG/ML
13 Aripiprazole and Prolactin Study Completed NCT01085383 Phase 4 Aripiprazole
14 Surgical Debulking of Pituitary Adenomas Completed NCT01371643 Phase 4 Octreotide LAR
15 A Post-Marketing Study of the Immunogenicity of Somatropin (Ribosomal Deoxyribo Nucleic Acid [rDNA] Origin) Injection (Nutropin AQ®) in Children With Growth Hormone Deficiency Completed NCT02311894 Phase 4 Somatropin
16 Determination of Method-specific Normal Cortisol and Adrenal Hormone Responses to the Short Synacthen Test Completed NCT00851942 Phase 4 Synacthen (Tetracosactrin)
17 GH and Cardiovascular Risk Factors Completed NCT01877512 Phase 4 Change in daily dosage of Growth Hormone
18 Endometriosis Patients Undergoing Quinagolide Treatment Completed NCT00625950 Phase 4
19 Treatment of Acromegaly With Somatostatin Analogs: GH vs. IGF-I as Primary Biochemical Target Completed NCT01618513 Phase 4 Sandostatin® LAR
20 An Open-label Phase 4 Study to Explore Immunogenicity of the Liquid Formulation of Saizen® in Subjects With Adult Growth Hormone Deficiency (AGHD) Completed NCT01806298 Phase 4 Saizen® solution for injection (referred as Saizen®)
21 Safety and Efficacy of SR-hGH (Sustained-release Human Growth Hormone, Declage Inj.) Completed NCT01605331 Phase 4 sustained-release recombinant human GH (SR-rhGH)
22 Effect of Somatropin on Left Ventricular Mass in Growth Hormone Deficient Adult Patients Completed NCT01562834 Phase 4 somatropin;placebo
23 Study to Evaluate the Efficacy and Safety of Sandostatin LAR at High Dose or in Combination Either With GH-receptor Antagonist or Dopamine-agonist in Acromegalic Patients Completed NCT01278342 Phase 4 Sandostatin LAR;pegvisomant;cabergoline
24 First Year Growth Response Associated Genetic Markers Validation Phase IV Open-label Study in Growth Hormone Deficient and Turner Syndrome Pre-pubertal Children: the PREDICT Pharmacogenetics Validation Study Completed NCT01419249 Phase 4
25 Is There a Sensibility Increased in the Growth Hormone at Child With Prader-Willi Syndrome? Completed NCT01298180 Phase 4 Growth hormone (Genotonorm® or Omnitrope®)
26 Norditropin NordiFlex® Device Compared to the Device Previously Used by Patients or Parents Completed NCT01245374 Phase 4
27 Short and Long Term Efficacy of Combined Cabergoline and Octreotide Treatment in Acromegalic Patients Completed NCT01014793 Phase 4 cabergoline
28 A Multicentre, Randomised, Open-label, Controlled Study to Evaluate the Effects of Saizen® on Cardiac Function in Growth Hormone Deficient(GHD) Subjects During the Transition Phase From Childhood to Adulthood Completed NCT01157793 Phase 4 r-hGH;r-hGH
29 Anterior Pituitary Hormone Replacement in Traumatic Brain Injury Completed NCT00957671 Phase 4 Human Growth Hormone;Placebo
30 Non Interventional Study For Patients Treated With Somavert® Completed NCT00858143 Phase 4
31 Comparison of a Needle-free Injection Method With a Needle-syringe Injection Method Completed NCT00990340 Phase 4
32 Growth Hormone and Glucose Metabolism Completed NCT00929799 Phase 4 recombinant human Growth Hormone (Genotropin® )
33 Study to Assess the Efficacy of an Extended Injection Interval Schedule of Lanreotide Autogel in Acromegalic Subjects Completed NCT00701363 Phase 4 Lanreotide Autogel 120 mg
34 Change in Quality of Life After Addition of Weekly 40 mg Pegvisomant/Placebo in Controlled Acromegalic Patients Completed NCT00642720 Phase 4 Pegvisomant
35 Lanreotide Autogel-120 mg as First-Line Treatment of Acromegaly Completed NCT00627796 Phase 4 Lanreotide-Autogel 120 mg
36 Acute Application of Pegvisomant and Octreotide in Acromegaly Completed NCT00595140 Phase 4 pegvisomant;combination with somatostatin analogue octreotide;combination with dopamine agonist cabergoline
37 Preoperative Octreotide Treatment of Acromegaly Completed NCT00521300 Phase 4 Octreotide
38 Easypod United States User Trial Completed NCT00689260 Phase 4
39 Predictive Factors of Response to Somatostatin Analogues in Acromegalic Patients With Persistent Disease Following Surgery Completed NCT00500227 Phase 4
40 Dose Escalation of Octreotide-LAR as First-Line Therapy in Resistant Acromegaly Completed NCT00461149 Phase 4 Octreotide-LAR
41 Liquid Somatropin Formulation in Children With Growth Hormone Deficiency Completed NCT00567385 Phase 4 somatropin
42 Efficacy of Octreotide Acetate and Cabergoline in Patients With Acromegaly Completed NCT00376064 Phase 4 Octreotide acetate and cabergoline/Octrotide and Somavert
43 Comparison of Two Growth Hormone Dosing Methods in Adults With Growth Hormone Deficiency Completed NCT00490191 Phase 4 Somatropin
44 Effect of 5 Years of GH Replacement on Atherosclerosis Completed NCT00462475 Phase 4 Recombinant Growth Hormone, Genotropin (Pfizer)
45 Cardiac Valve Complications in Prolactinomas Treated With Cabergoline Completed NCT00460616 Phase 4 Cabergoline
46 A Post Marketing Surveillance Study for NutropinAq® in Adults With Growth Hormone Deficiency Completed NCT00455884 Phase 4
47 Growth Hormone and Endothelial Function in Children Completed NCT00373386 Phase 4 growth hormone
48 A Study to Evaluate the Risk of Developing a Heart Condition Called Valvular Regurgitation in Patients With Acromegaly Treated With Either Lanreotide or Octreotide Completed NCT00234520 Phase 4
49 Lanreotide Autogel in Patients With Acromegaly Previously Treated With Octreotide LAR Completed NCT00216398 Phase 4 Lanreotide (Autogel formulation)
50 Octreotide Efficacy and Safety in First-line Acromegalic Patients Completed NCT00171886 Phase 4 Octreotide

Search NIH Clinical Center for Hypothalamic Disease

Cochrane evidence based reviews: hypothalamic diseases

Genetic Tests for Hypothalamic Disease

Anatomical Context for Hypothalamic Disease

MalaCards organs/tissues related to Hypothalamic Disease:

38
Pituitary, Testes, Brain, Bone, Hypothalamus, Heart, Liver

Publications for Hypothalamic Disease

Articles related to Hypothalamic Disease:

(show all 11)
# Title Authors Year
1
Comparison of body composition, basal metabolic rate and metabolic outcomes of adults with Prader Willi syndrome or lesional hypothalamic disease, with primary obesity. ( 23318724 )
2013
2
Hypothalamic disease: neurosecretory dysfunction and parasellar lesions. ( 9174692 )
1997
3
Neurologic manifestations of hypothalamic disease. ( 1480755 )
1992
4
Hypothalamic disease in association with dysgenesis of the corpus callosum. ( 2813236 )
1989
5
Hypothalamic disease presenting as amenorrhoea: value of computed tomography. ( 4084469 )
1985
6
Radiological aspects of pituitary--hypothalamic disease. ( 330035 )
1977
7
Evidence that acromegaly is not a hypothalamic disease. ( 4363384 )
1973
8
A comparative study of endocrine tests in hypothalamic disease. Circadian periodicity of plasma 11-OHCS levels, plama 11-OHCS and growth hormone response to insulin hypoglycemia and metyrapone responsiveness. ( 5697039 )
1968
9
Evaluation of ACTH reserve in pituitary-hypothalamic disease. ( 4288690 )
1966
10
Dysrhythmia associated with proved hypothalamic disease. Fourteen- and six-per-second dysrhythmia. ( 14465902 )
1962
11
Endocrine and other clinical manifestations of hypothalamic disease; a survey of 60 cases, with autopsies. ( 13130650 )
1954

Variations for Hypothalamic Disease

Expression for Hypothalamic Disease

Search GEO for disease gene expression data for Hypothalamic Disease.

Pathways for Hypothalamic Disease

GO Terms for Hypothalamic Disease

Cellular components related to Hypothalamic Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.55 CRH GH1 GHRH GNRH1 POMC
2 extracellular region GO:0005576 9.1 CRH GH1 GHRH GNRH1 POMC PRL
3 endosome lumen GO:0031904 8.96 GH1 PRL

Biological processes related to Hypothalamic Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 G-protein coupled receptor signaling pathway GO:0007186 9.76 CRH GHRH GNRH1 POMC
2 cell-cell signaling GO:0007267 9.58 GHRH GNRH1 POMC
3 positive regulation of cAMP biosynthetic process GO:0030819 9.43 CRH GHRH
4 positive regulation of multicellular organism growth GO:0040018 9.37 GH1 GHRH
5 positive regulation of JAK-STAT cascade GO:0046427 9.32 GH1 PRL
6 JAK-STAT cascade involved in growth hormone signaling pathway GO:0060397 9.26 GH1 PRL
7 positive regulation of insulin-like growth factor receptor signaling pathway GO:0043568 9.16 GH1 GHRH
8 female pregnancy GO:0007565 9.13 CRH GNRH1 PRL
9 regulation of receptor activity GO:0010469 9.02 GH1 GHRH GNRH1 POMC PRL

Molecular functions related to Hypothalamic Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 neuropeptide hormone activity GO:0005184 9.16 CRH POMC
2 hormone activity GO:0005179 9.02 CRH GH1 GNRH1 POMC PRL
3 prolactin receptor binding GO:0005148 8.96 GH1 PRL

Sources for Hypothalamic Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....